OS1

Otsuka Holdings Co., Ltd. · TRADEGATE:OS1

65.50 EUR−0.5000 −0.76%

Otsuka Holdings Co., Ltd. (TRADEGATE:OS1) last traded at 65.50 EUR, down 0.76% on the day. Over the past year the stock is up 41.16%. Its 52-week range is 44.60 to 72.00. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open65.50

Day range65.00 – 65.50

52-week range44.60 – 72.00

Volume2

Average volume (10 days)20

Market cap (USD)38.93 B

P/E15.87

EPS (TTM) (USD)4.68

Dividend yield1.44%

Beta (1 year)0.4444

Revenue (TTM) (USD)17.11 B

Employees37.76 K

Performance

−7.75%1 week

+1.55%1 month

+0.77%3 months

+5.65%6 months

+32.59%Year to date

+41.16%1 year

Technical reading

Bearish

Daily summary of what 11 oscillators and 15 moving averages show. See every indicator

Latest headlines

Otsuka: Strong pharmaceutical growth lifted profit; FY2026 business profit guidance rose to ¥500bnQuartr · 30 Oct 2026
Otsuka Holdings 9M Results Rise; Lifts FY26 Earnings View, Backs Revenue Forecast; Stock Downdpa-AFX · 30 Oct 2026
Otsuka Holdings Co., Ltd. - To Retire Treasury Shares Worth 0.84% Of Outstanding Stock On December 11Reuters · 30 Oct 2026
Otsuka: Strong 9M growth lifted FY2026 profit guidance, while revenue guidance held steadyQuartr · 30 Oct 2026
Gujarat woos Japanese investors in Tokyo ahead of Vibrant Gujarat summit-2027Business Line · 21 Oct 2026
Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALSReuters · 22 Sep 2026
Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary EndpointReuters · 22 Sep 2026
Otsuka Holdings Co., Ltd. - Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung CancerReuters · 13 Sep 2026

Market data is delayed as each exchange requires (see data coverage). SuperCharting is charting software and gives no investment advice.